Welcome, visitor! [ Login

Biotechnology Mergers and Acquisitions 全球生物科技并购交易金额 (January 1, 2009 – June 30, 2012 )

Medical Blog 2012-11-20

A new three-and-a-half-year biotechnology M&A report published by Irving Levin Associates, Inc. shows a continued decline in biotechnology transaction activity during the reported period. Merger and acquisition activity in the biotechnology sector of the health care industry gradually declined in terms of the number of deals announced from January 2009 through 2011. The year 2012 looks to be on track to equal the number of deals in 2011, according to corresponding data from the first six months of both years.

The number of transactions each year and respective annual dollar volume, according to The Biotechnology Acquisition Report, Second Edition, 2012, are listed in the table below.

 
Biotechnology Mergers and Acquisitions January 1, 2009 – June 30, 2012
Year         Number of Transactions        
Dollar Volume of
Transactions
2009         193         $47,000,000,000
2010         129         $61,000,000,000
2011         80         $33,000,000,000
2011 First 6 Months         48         $12,000,000,000
2012 First 6 Months         49         $15,000,000,000
                     

Continue reading …

2154 total views, 0 today

Medical Device Mergers and Acquisitions 全球医疗设备并购交易金额(January 1, 2009 – June 30, 2012 )

Medical Blog 2012-11-20

Merger and acquisition activity in the Medical Device sector of the health-care industry has proceeded at a fairly steady pace over the past three and a half years in terms of the number of deals announced from January 2009 through June 2012—a trend that appears to be continuing according to Irving Levin Associates’ new report The Medical Device Acquisition Report, Second Edition, 2012 In fact, Medical Device has been the most active M&A sector in the entire health-care industry through the first half of 2012.

During the three and one-half year period covered in this report, the Medical Device M&A market accounted for 632 transactions. The 88 deals announced in the first half of 2012 amount to about 14% of those deals, a level of activity that is on target to match or exceed the average number of deals transacted in each of the previous three years.

The number of transactions each year and respective annual dollar volume, according to The Medical Device Acquisition Report, Second Edition, 2012, are listed in the table below.

Medical Device Mergers and Acquisitions January 1, 2009 – June 30, 2012
Year  
Number of
Transactions
 
Dollar Volume of
Transactions
2009   177   $13,900,000,000
2010   185   $47,700,000,000
2011   173   $65,730,000,000
2011 First 6 Months   89   $48,150,000,000
2012 First 6 Months   88   $14,900,000,000

Continue reading …

2090 total views, 0 today

2012年生物医药领域TOP20(1-8月)合作交易盘点 M&A

Medical Blog 2012-10-30

2012年已进入第三季度末,生物医药领域的合作开发交易究竟行情如何?

3项10亿美元以上交易

数据显示,规模上10亿美元的交易不多,只有3项交易过此门槛。

施贵宝和阿斯利康的合作交易金额最大。该交易涉及糖尿病新药开发和销售领域的全面合作,阿斯利康支付施贵宝34亿美元,享有施贵宝收购Amylin药业之后,在糖尿病新药开发及商业运作方面的同等权益。阿斯利康为其支付一半的费用,形成权益对等的合作体及合资企业。另外,双方还就开发糖尿病复方新药达成了长期合作意向。这种合作模式,虽然不是业内首创的模式,但也属近几年所看到的专项合作领域规模比较大的交易。

第二项大型合作交易是雅培和Galapagos之间达成的技术转让协议,雅培支付13.5亿美元,从Galapagos获得风湿性关节炎的新药候选物GLP0634。该项目正处于临床Ⅱ期试验,估计要到2014年完成。这是雅培药业正式与雅培剥离成为独立药业公司后,对外显示其资金、信心和开发实力的标志性交易。

第三项是默沙东和Endocyte之间签署的价值10亿美元的合作交易,默沙东获得后者开发的抗癌新药vintafolide,这是用于治疗肺癌和宫颈癌的新药和伴随诊断试剂。Endocyte的新药vintafolide目前正处于临床试验中晚期,其中用于治疗宫颈癌及其伴随诊断的产品处于临床Ⅲ期,用于治疗肺小细胞癌适应症的正处临床Ⅱ期。作为交换,Endocyte获得1.2亿美元的首付,这几乎相当于该公司签署合约前1.8亿美元的市值。如果临床试验成功,可获得8.8亿美元的里程碑支付。 Continue reading …

2272 total views, 1 today

Top M&A deals in pharmaceuticals in 2010 & 2011

Medical Blog 2012-07-14

Top M&A deals in pharmaceuticals in two years. Big mergers and buyouts expected this year did not materialise

Year Target Buyer Deal value (Rs cr)
2011 Wockhardt Ltd 
(nutrition business)
Danone SA 1,576
2011 Kilitch Drugs 
(certain assets)
Akorn, Inc 200
2010 Piramal Healthcare 
(domestic business)
Abbott Inc 17,500
2010 Paras Pharmaceuticals Ltd Reckitt Benckiser  
    Group Plc 3,260
2010 RFCL Ltd Avantor Performance 
Materials Holdings Inc
500
Source: Companies

More

2758 total views, 1 today

全球医药业并购 Pharmaceutical M&A deals in 2009

Medical Blog 2012-07-14

Following 2008, when pharmaceutical sector merger and acquisition activity was on a relatively small scale in terms of the size of deals announced, 2009 was a bumper year.

According to The Pharma Letter’s records, there were 92 pharmaceutical acquisitions consummated during 2009 (with several others announced but failing), compared with 113 the previous year. Of the 2009 announcements, 16 deals exceeded a value of $1 billion (see separate story for a full commentary on the deals.) The full list can be seen below.

 

Company Partner Deal value $ Complete
Abbott Labs (US) Advanced Medical Optics (US) $2.8 billion Feb 2009
Abbott (US) Visiogen $400.0 million Oct 2009
Abbott (US) Solvay (Belgium) Pharma unit $6.6 billion 1st-qtr 2010
Adamis Pharma (USA) La Jolla Pharma Undisclosed TCB
Alcon (Swiss) ESBATech (Swiss) $439.0 million TBC
AstraZeneca (UK) Novexel (France) $505.0 million TCB
BioMarin (US) Huxley Pharma (US) c$58.5 million Oct 2009
BioSante Pharma (US) Cell Genesys (US) $38.0 million Oct 2009
Biovitrum (Sweden) Swedish Orphan (Sweden) $493.0 million Dec 2009
Bristol-Myers Squibb (US) Medarex (US) $2.4 billion Sep 2009
Celgene (US) Gloucester Pharma (US) $640.0 million 1st-qtr2010
Cellidex Thera (US) CuraGen (US) $94.5 million Oct 2009
Cephalon (US) Arana Therapeutics (Australia) $205.0 million Aug 2009
Dainippon Sumitomo (Japan) Sepracor (US) $2.6 billion Oct 2009
Deerfield Management NitroMed (US) $36.0 million Feb 2009
Eisai (Japan) AkaRx (US) $255.0 million TBC
Endo Pharma (US) Indevus Pharma (US) $637.0 million Feb 2009
Evolva (Swiss) Arpida (Swiss) Undisclosed Dec 2009
Evotec (Germany) RSIPL (India) $3.5 million Aug 2009
Genesis Pharma (US) Hongrui Pharma (China) $16.0 million Mar 2009
Gen-Probe (US) Tepnel Life Science (UK) $132.2 million Apr 2009
Gilead Sciences (US) CV Therapeutics (US) $1.4 billion Apr 2009
GlaxoSmithKline (UK) Bristol-Myers Squibb (Pakistan) $365.0 million 2009
GlaxoSmithKline UK) UCB Emerging Market units $676.0 million 2009
GlaxoSmithKline (UK) Stiefel Labs (US) $3.6 billion July 2009
GlaxoSmithKline (UK) Aspen Pharmacare (19% stake) $593.6 million est Dec 2009
GlaxoSmithKline (UK) Intercell (Austria; 5% stake) $57.4 million Dec 2009
GPC Biotech (German) Agennix (US) Undisclosed Mar 2009
HalcyGen (Australia) Mayne Pharma Int (Australia) 415.0 million Oct 2009
Hard to Treat Medicine (China) Shenzen Mellow Hope (China) Undisclosed Mar 2009
Helsinn (Switzerland) Sapphire Therapeutics Undisclosed Feb 2009
Hisamitsu Pharma (Japan) Noven Pharma (US) $428.0 million Aug 2009
Hospira (US) Orchid Chem & Pharma (India) (injectable generics business) $400.0 million TBC
Integrated DNA Tech (US) VH Bio’s oligo business Undisclosed 2009
Inviragen (US) SingVax (Singapore) Undisclosed Oct 2009
Johnson & Johnson (US) Cougar Biotechnology $1.0 billion Jul 2009
Johnson & Johnson (US) Crucell – 18% stake $443.3 million Sept 2009
Laboratory Corp of America (US) Monogram Biosciences (US) $106.7 million Aug 2009
LEO Pharma (Denmark) Peplin (US, Australia) $287.5 million Nov 2009
Ligand Pharma (US) Neurogen (US) $11.6 million Dec 2009
Ligand Pharma (US) Metabasis Thera (US) $3.2 million Nov 2009
Lundbeck (Denmark) Ovation Pharma (US) $900.0 million Mar 2009
Lundbeck (Denmark) LifeHealth (UK) $147.0 million Jul 2009
Medicines Co (US) Targanta Therapeutics $42.0 million Feb 2009
MediciNova (US) Avigen (US) $37.0 million Dec 2009
Merck & Co (US) Schering-Plough (US) $41.1 billion Nov 2009
Merck & Co (US) Avecia Biologics (UK) Under $1 billion TBC
Merck KGaA (Germany) Bangalore Genei (India) Undisclosed Oct 2009
Midas BidCo (Goldshield management team) Goldshield (UK) $280 million Dec 2009
Mylan (US) Matrix Labs (India) (29% not already owned) $133.0 million 2009
Myriad Pharma (US) Javelin Pharma (US) $96.0 million TBC
Nippon Chemiphar (Japan) Nihon Pharma (taking over Ranbaxy share of the JV) Undisclosed TCB
Novartis (Swiss) EBEWE Pharma (Austria) $1.2 billion Sept 2009
Novartis (Swiss) Zheijian Tianyuan (China) $125 million TBC
Novartis (Swiss) Corthera (US) $120.0 million (Plus possible $500 million on milestone successes) TCB
Onyx Pharma US) Proteolix (US) $850.0 million Nov 2009
Opko Health (US) Pharma Genexx (Chile) $16.0 million Dec 2009
OXiGENE (US) VaxGen (US) $22.0 million TBC
Pfizer (US) Wyeth (US) $68.0 billion Oct 2009
Pharmexa (Denmark) Affitech (Norway) Merger Jun 2009
Piramel (India) Minrad International (US) $40.0 million 2009
PPD (US) Magen Biosciences (US) $14.5 billion Apr 2009
Progen (Australia) Avexa (Australia) $55.3 million 2009
Proximagen Neuro (UK) Cambridge Biotech (UK) (acquired from Biovitrum of Sweden) Undisclosed Nov 2009
Qiagen (Netherlands) SA Biosciences (US) $90.0 million Dec 2009
Raptor Pharma (US) TorreyPines (US) Undisclosed Sept 2009
Roche (Swiss) Genentech (USA) $46.8 billion (42% not already owned) Apr 2009
Sanofi-Aventis (France) Zentiva (Czech) $2.3 billion Mar 2009
Sanofi-Aventis (France) Medley SA (Brazil) $220.0 million Mid-2009
Sanofi-Aventis (France) Laboratorios Kendrick (Mexico) Undisclosed Apr 2009
Sanofi-Aventis (France) BiPar Sciences (US) Undisclosed 2nd qtr
Sanofi-Aventis (France) Shantha Biotechnics (India) $613 million Aug 2009
Sanofi-Aventis (France) Fovea Pharma (France) $542 million Dec 2009
Sanofi-Aventis (France) Chattem (US) $1.9 billion TCB
Santhera (Swiss) Juvantia Pharma Undisclosed Oct 2009
Schwabe Pharma (German) Dr Peithner Holdings Undisclosed May 2009
Sigma-Tau (Italy) Enzon (US) Specialty Pharma business $327.0 million Dec 2009
Silence Therapeutics UK) Intradign (US) Undisclosed Jan 2010
Simcere Pharma (China) Jiansu Yanshen (China) 37% stake $28.6 million 2009
Sinclair Pharma (UK) Lab Novo Pharma (Spain) Remaining 50% holding Undisclosed Feb 2009
Stem Cells (USA) Stem Cells Sciences (UK) Undisclosed May 2009
Takeda (Japan) IDM Pharma (US) $75.0 million July 2009
Teva (Israel) OncoGenex (US) (small stake) $10.0 million TCB
Teva (Israel) Taisho Pharma Ind (Japan) (majority stake min.66.7%) Undisclosed Dec 2009
Tolmar (US) Zila (US) $4.0 million Sept 2009
Tolmar (USA) QLT (Canada)’s US unit $230.0 million Oct 2009
Tongjitang (China) Anhui Jingfanag (China) $8.8 million Apr 2009
Valeant (US) EMO-PHARMA (Poland) $28.0 million May 2009
Valeant (USA) Lab Dr Renaud (Canada) $21.8 million TCB
Warner Chilcott (Irish) Procter & Gamble Rx Pharma business $3.2 billion Oct 2009
Watson Pharma (US) Arrow Pharma (US) $1.75 billion Dec 2009
Wyeth (US) Thiakis (UK) $150.0 million Jan 2009

3215 total views, 1 today

全球制药业并购 2011 Pharmaceutical M&A deals in 2011

Medical Blog 2012-07-14

 

Pharmaceutical M&A deals in 2011

Details for the 129 M&A announcements recorded by The Pharma Letter are provided in the full table below:
Compared with 117 in 2010, which was then a record number (Pharmaceutical M&A deals in 2010, The Pharma Letter January 13, 2011).

 

Company

  

Takeover candidate

  

 

Deal Value US $ *

  

 

Completed

  

 

Abcam (UK) 

 

MitoSciences (UK) 

 

Undisclosed 

 

May-11 

 

Abcam (UK) 

 

Ascent Scientific (UK) 

 

$15.9 million 

 

Sep-11 

 

Acino Pharma (Switz) 

 

Mepha (Switz) MENA, Latin America and Asia business units from Teva subsidiary Cephalon 

 

$226.0 million 

 

Dec-11 

 

ADVENTRX Pharma (US) 

 

SynthRx (US) 

 

Undisclosed stock deal 

 

Apr-11 

 

Affymetrix (US) 

 

eBioscience (US) 

 

$330.0 million 

 

Dec-11 

 

Alere (US) 

 

Axis-Shield (UK) 

 

$365.0 million 

 

Bid announced July; Alere went hostile Aug 5; closed Nov 2011 

 

Alexion Pharma (US) 

 

Taligen Therapeutics (US) 

 

$111.0 million 

 

Feb-11 

 

Alexion Pharma (US) 

 

Enobia Pharma (Canada) 

 

$610.0 million upfront and $470 million contingent on regulatory milestones 

 

Exp 1st-qtr 2012 

 

Alkermes (US) 

 

Elan Drug Technologies unit of Elan Corp (Ireland) 

 

$960 million cash and stock deal 

 

Sep-11 

 

Allergan (US) 

 

Vicept Thera (US) 

 

$275.0 million, of which $75 mill upfront 

 

Jul-11 

 

Allozyne (US) 

 

Poniard Pharma (US) 

 

Stock exchange deal 

 

Announced June 23. Deal called off Dec 2011 

 

Amgen (US) 

 

BioVex (US)   

 

$1.0 billion. Paid $435 million upfront with further $575 million in milestones 

 

Mar-11 

 

Amgen (US) 

 

Bergamo (Brazil) 

 

$215.0 million 

 

Apr-11 

 

Ancient Pharma (US) 

 

Timm Medical (US) 

 

Undisclosed 

 

Jan-11 

 

Apricus Biosciences (US) 

 

US subsidiary of Topotarget A/S (Denmark) 

 

$2.0 million plus $2 million stock based on milestones 

 

Dec-11 

 

Asahi Kasei Pharma (Japan) 

 

Artisan Pharma (US) 

 

Undisclosed 

 

Nov-11 

 

Astellas (Japan) 

 

Perseid Therapeutics (US) Buys Maxygen’s stake in JV 

 

$76.0 million 

 

May-11 

 

AstraZeneca (UK) 

 

Guangdong BeiKang Pharma (China) 

 

Undisclosed 

 

Exp 1st-qtr 2012 

 

Axcan (Canada) 

 

Mpex (US) 

 

$230.0 million 

 

Nov-11 

 

Baxter Int (US) 

 

Prism Pharma (US) 

 

$388.0 million of which $170 million upfront 

 

June 2-011 

 

Baxter Int (US) 

 

Baxo Corp (US) 

 

$380.0 million 

 

Nov-11 

 

Baxter Int (US) 

 

Synovis Life Technologies (US) 

 

$325.0 million 

 

Exp 1st-qtr 2012 

 

Biostar Pharma (US) 

 

Shaanxi Weinan (China) 

 

$9.6 million stock deal 

 

Oct-11 

 

Biotie Thera (Finland) 

 

Synosia Thera (Switz) 

 

$121.5 million 

 

Feb-11 

 

Biotie Thera (Finland) 

 

Newron Pharma (Italy) 

 

$60.8 million 

 

Deal cancelled 

 

BioTime (US) 

 

Glycosan Bio Systems (US) 

 

Undisclosed stock deal 

 

Mar-11 

 

BioTime (US) 

 

Cell Targeting (US) 

 

Undisclosed stock deal 

 

Jan-11 

 

Bluefish Pharma (Sweden) 

 

BMM Pharma unit of Medivir (Sweden) 

 

$6.0 million 

 

Aug-11 

 

Bristol-Myers Squibb (US) 

 

Amira Pharma (US) 

 

$325.0 million plus $150.0 million milestones 

 

Sep-11 

 

Celesio (Germany) 

 

OncoProd (Brazil) 60% stake 

 

Undisclosed 

 

Oct-11 

 

Cephalon (US) 

 

Gemin X Pharma (US) 

 

$225.0 million plus milestones of up to $300 million 

 

2011 

 

Cephalon (US) 

 

ChemGenex (Australia) 

 

$231.0 million 

 

2011 

 

Cornerstone Therapeutics (US) 

 

Cardiokine (US) 

 

Undisclosed 

 

Dec-11 

 

Cubist Pharma (US) 

 

Adolor Corp (US) 

 

$221 upfront plus contingent payment right worth up to $225 million 

 

Dec-11 

 

Cynapsus Therapeutics (Canada) 

 

Adagio Pharma (Canada) 

 

$5.55 million 

 

Dec-11 

 

Daiichi Sankyo (Japan) 

 

Plexxikon (US) 

 

$805.0 million 

 

Apr-11 

 

Elan (Ireland) 

 

Proteostasis Therapeutics (US) 

 

$20.0 million for 24% equity stake 

 

May-11 

 

Endo Pharma (US) 

 

American Medical Systems (US) 

 

$2.9 billion 

 

Jun-11 

 

Evotec (Germany) 

 

Kinaxo (Germany) 

 

$17 million 

 

Apr-11 

 

Ewopharma (Swiss) 

 

Newport Pharma subsid of Immdal (Ireland) 

 

Undisclosed 

 

Oct-11 

 

Farmsintez (Russia) 

 

Kevelt (Estonia) 

 

Undisclosed 

 

Jan-11 

 

Ferring Pharma (Swiss) 

 

Cytokine PharmaSciences (US) 

 

Undisclosed 

 

Oct-11 

 

Footstar (US) 

 

CPEX Pharma (US) 

 

$76.6 million 

 

Apr-11 

 

Forest Labs (US) 

 

Clinical Data (US) 

 

$1.2 billion 

 

Apr-11 

 

Fosun Pharma (China) 

 

Aleph Biomed (China) 75% stake 

 

$102.0 million 

 

Feb-11 

 

Galenica (Switz) 

 

Vifor Uriach, the joint venture with Grupo Uriach (Spain) 

 

Undisclosed 

 

Nov-11 

 

Gilead Sciences (US) 

 

Calistoga Pharma (US) 

 

$375.0 million plus possible $225 million in milestones 

 

Apr-11 

 

Gilead Sciences (US) 

 

Pharmasset (US) 

 

$11.0 billion 

 

Exp 1st-qtr 2011 

 

Grifols (Spain) 

 

Talecris Biotherapeutics (US) 

 

$3.4 billion 

 

Jun-11 

 

Hikma Pharma (Jordan) 

 

Unimark Remedies (India) – 25% stake 

 

$33.3 million 

 

May-11 

 

Hikma Pharma (Jordan) 

 

Baxter injectable generics business 

 

$112.0 million (First announced in 2010) 

 

May-11 

 

Hikma Pharma (Jordan) 

 

Hubei Haosun (China) minority stake 

 

$5.0 million 

 

2011 

 

Hikma Pharma (Jordan) 

 

Promopharm (Morocco) 

 

$111.2 million for 63.9% stake; intends to buy remainder 

 

Due end Jan 2012 

 

Histogenics (US) 

 

ProChon Biotech (Israel) 

 

Undisclosed stock-for-stock deal 

 

May-11 

 

Intrexon (US) 

 

Immunologix (US) 

 

Undisclosed 

 

Oct-11 

 

IS Pharma (UK) 

 

Helsinn Healthcare (Switz) Helsinn Birex unit in Ireland 

 

$6.0 million 

 

Feb-11 

 

Jazz Pharma (US) 

 

Azur Pharma (Irish) 

 

All stock merger with Jazz shareholders owning nearly 80%  

 

Dec-11 

 

Johnson & Johnson (US) 

 

Synthes (Switz) 

 

$21.3 billion 

 

EU Commission launched investigation Nov 2011, decision due Apr 2012 

 

Johnson & Johnson (US) 

 

J&J-Merck Consumer (US). Buys Merck & Co’s 50% stake in JV 

 

$175.0 million 

 

Sep-11 

 

Kyowa Hakko Kirin (Japan) 

 

ProStrakan (UK) 

 

$474.3 million 

 

Apr-11 

 

Kohlberg Kravis Roberts (US) 

 

Capsugel (US) a unit of Pfizer 

 

$2.38 billion 

 

Aug-11 

 

Ligand Pharma (US) 

 

CyDEX Pharma (US) 

 

$31.2 million, plus contingent payments 

 

Jan-11 

 

Eli Lilly (US) Elanco unit 

 

Janssen Pharma animal health business 

 

Undisclosed 

 

Jul-11 

 

Lupin (India) 

 

I’rom Pharma unit of I’rom Holdings (Japan) 

 

Undisclosed 

 

Nov-11 

 

Medicis (US) 

 

Graceway Pharma (US) 

 

$455.0 million 

 

Dec-11 

 

Medivir (Sweden) 

 

BioPhausia (Sweden) 

 

$90.8 million 

 

Jun-11 

 

Merck & Co (US) 

 

Inspire Pharma (US) 

 

$430.0 million 

 

May-11 

 

Merck KGaA (Germany) 

 

Beijing Skywing (China) 

 

$18.2 million 

 

Jan-11 

 

Merck KGaA (Germany) 

 

Microbiology business of Biotest AG (Germany) 

 

Undisclosed 

 

Aug-11 

 

Menarini (Italy) 

 

Invida (Singapore) 

 

Undisclosed) 

 

Nov-11 

 

Mitsui & Co (Japan) 

 

Mercian (Japan) pharma and chemical business 

 

Undisclosed 

 

Jun-11 

 

NeoStem (US) 

 

Progenitor Cell Therapy (US) 

 

About $20.0 million 

 

Oct-11 

 

Nitto Denko (Japan) 

 

Avecia Biotech (US) 

 

Undisclosed 

 

Feb-11 

 

Novartis (Switz) 

 

Genoptix (US) 

 

$470.0 million 

 

Jun-11 

 

Novartis (Switz) 

 

Zhejiang Tianyuan (China) – 85% stake 

 

$125.0 million 

 

Mar-11 

 

Novelos Thera (US) 

 

Cellectar (US) 

 

Stock deal 

 

Apr-11 

 

Nycomed (Switz) 

 

Lab Farmacol (Colombia) 

 

Undisclosed 

 

Jun-11 

 

OPKO Health (US) – controlled by Teva 

 

FineTech Pharmaceutical (Israel) 

 

$27.5 million 

 

Dec-11 

 

Paladin Labs (Canada) 

 

Labopharm (Canada) 

 

$20.6 million 

 

Oct-11 

 

Par Pharmaceutical (US) 

 

Edict Pharmaceuticals (India) 

 

$37.6 million plus assumption of debt 

 

Nov-11 

 

Par Pharma (US) 

 

Anchen Pharma (US) 

 

$410.0 million 

 

Nov-11 

 

Perrigo (US) 

 

Paddock Labs (US) 

 

$540.0 million 

 

Jul-11 

 

Pfizer (US) 

 

Ferrosan (Denmark) Consumer health unit 

 

Undisclosed 

 

Dec-11 

 

Pfizer (US) 

 

Icagen (US) 

 

$56.0 million enterprise value 

 

Oct-11 

 

Pfizer (US) 

 

Excaliard Pharma (US) 

 

Undisclosed 

 

Dec-11 

 

Pharmstandard (Russia) 

 

PJSC Biolek (Russia) 

 

Undisclosed 

 

Jan-11 

 

Qiagen (Netherlands) 

 

Cellestis (Australia) 

 

$355.0 million 

 

Sep-11 

 

Qiagen (Netherlands) 

 

Ipsogen (France) 

 

$101.0 million 

 

Jul-11 

 

Recordati (Italy) 

 

Frik Ilac (Turkey) 

 

$130 million 

 

Sep-11 

 

Repligen (US) 

 

Novozymes Biopharma Sweden unit of Denmark’s Novozymes 

 

$22.7 upfront and $5.6 million milestones 

 

Dec-11 

 

Roche (Swiss) 

 

PVT Probenverteiltecknik (Germany) 

 

$90.0 million, plus performance-related milestone 

 

May-11 

 

Roche (Swiss) 

 

mtm laboratories (Germany) 

 

$268.4 million 

 

Aug-11 

 

Roche (Swiss) 

 

Anadys Pharma (US) 

 

$230.0 million 

 

Nov-11 

 

Rxi Pharma (US) 

 

Apthera (US) 

 

$7.2 million plus milestones 

 

Apr-11 

 

Salix Pharma (US) 

 

Oceana Therapeutics (US) 

 

$300.0 million 

 

Dec-11 

 

Sanofi (France) 

 

Genzyme (US) 

 

$21.1 billion plus CVR 

 

Apr-11 

 

Sanofi (France) 

 

OTC business of Universal Medicare (India) 

 

$100 million (Est) 

 

Nov-11 

 

Santen Pharma (Japan) 

 

Novagali (France) 

 

50.55% stake with aim of buying remained for around $135 million 

 

First tranche completed Oct 2011 

 

SciClone Pharma (US) 

 

NovaMed Pharma (China) 

 

$104.8 million cash and shares, with $61.8 upfront 

 

Apr-11 

 

Shire (Ireland) 

 

Advanced BioHealing (US) 

 

$750.0 million 

 

Jun-11 

 

Sinclair IS (UK) 

 

Advanced Bio-Technologies (US) 

 

$32.8 million 

 

Ann Dec 8, close exp 1st-qtr 2011 

 

Sinclair Pharma (UK) 

 

IS Pharma (UK) 

 

Est $208 million stock deal merger 

 

2011 

 

SOHM (US) 

 

Novatrend Medicament (India) 

 

Undisclosed 

 

Nov-11 

 

STADA Arzneimittel (Germany) 

 

Generics business of Spirig Pharma (Switz) 

 

$109.2 million 

 

Exp 1st-qtr 2012 

 

Sucampo Pharma (US) 

 

Sucampo AG (Switz) and Sucampo AG Japan (Japan) 

 

$80.0 million 

 

Jan-11 

 

Sun Pharma (India) 

 

Caraco Pharma (US) Remaining 24.2% shares 

 

$5.25/share 

 

Jun-11 

 

SuperGen (US) 

 

Astex Therapeutics (UK) 

 

$25.0 million plus $30 million deferred 

 

Jul-11 

 

Synageva BioPharma (US) 

 

Trimeris (US) 

 

All stock deal for Trimeris which has market cap of $63.6M 

 

Jul-11 

 

Takeda (Japan) 

 

Fate Therapeutics (US) Unspecified stake 

 

Undisclosed 

 

May-11 

 

Takeda (Japan) 

 

Nycomed (Switz) 

 

$13.68 billion 

 

Sep-11 

 

Takeda (Japan) 

 

Intellikine (US) 

 

$190.0 million up front plus $120 million in contingent milestones 

 

Exp Jan 2012 

 

Teva Pharma Industries (Israel) 

 

Infarmasa (Peru) 

 

Undisclosed 

 

Jan-11 

 

Teva Pharma Industries (Israel) 

 

Cephalon (US) 

 

$6.8 billion 

 

Oct-11 

 

Teva (Israel) 

 

Taiyo Pharma (Japan) 100% stake 

 

$934.0 million 

 

Jul-11 

 

Teva (Israel) 

 

CureTech (Israel) increases equity stake to 75% 

 

$19.0 million plus $50 million R&D funding 

 

Oct-11 

 

Teva (Israel) 

 

Teva-Kowa-Pharma, a joint venture with Kowa (Japan) 

 

$150.0 million for Kowa’s 50% share 

 

Oct-11 

 

The Medicines Company (US) 

 

GeNO (US) undisclosed non-majority stake 

 

Undisclosed 

 

Dec-11 

 

Valeant Pharma (Canada) 

 

PharmaSwiss (Switz) 

 

$480.0 million 

 

Mar-11 

 

Valeant Pharma (Canada) 

 

Sanitas (Lithuania) 

 

$444.4 million 

 

Aug-11 

 

Valeant (Canada) 

 

Dermik (Canada & US) subsidiary of Sanofi (France) 

 

$422.5 million 

 

Dec-11 

 

Valeant (Canada) 

 

Ortho Dermatologics (unit of Johnson & Johnson)  

 

$345.0 million 

 

Ann july; FTC appro gained Dec 12 2011 

 

Valeant (Canada) 

 

Afexa Life Sciences (Canada) 

 

$76.9 million 

 

Completed Dec 2011. Ann. Aug 31 in Battle with Paladin for control 

 

Valeant (Canada) 

 

iNova (Australia) 

 

$703.8 million (including A$75 million contingent payment 

 

Dec-11 

 

Valeant (Canada) 

 

ISTA Pharma (US) 

 

$327.0 million 

 

Ann Nov but rejected, and Valeant went hostile Dec 2011 

 

ViroPharma (US) 

 

DuoCort Pharma (Sweden) 

 

$164.0 million 

 

Nov-11 

 

Watson Pharma (US) 

 

Specifar Pharma (Greece) 

 

$562.0 million plus 400 million-euro contingent 

 

May-11 

 

XTL Biopharma (Israel) 

 

MinoGuard (Israel) technology 

 

Undisclosed 

 

Nov-11 

 

Zydus Cadila (India) 

 

Nesher Pharma generics unit of K-V Pharmaceutical US) 

 

$60.0 million 

 

Aug-11 

 

Zydus Cadila (India) 

 

Biochem (India) 

 

Undisclosed 

 

Dec-11 

 

 

* Where not announced in US dollars, transaction values are calculated at the exchange rates prevailing at the time of announcement.

4652 total views, 0 today

2007年全球制药业前10大并购案

Medical Blog 2012-07-14

2007年全球制药业前10大并购案(按涉及金额排序)
 
时间
收购方
被收购方
涉及金额
(亿美元)
结果
11月19
先灵葆雅公司
荷兰Organon BioSciences
161
前者的人用与动物用医药产品种类更加丰富,研发中品种提高
6月19
阿斯利康
美国medimmune
157
将经营触角延伸到疫苗以及其他生物技术产品
2月7
默克
Serono  SA
131
完成公司的生物转型
10月2
Mylan
默克的非专利药业务
69
向新药发展线补充400种新产品,成为全球非专利药第三强
1月4
比利时UCB
德国Schwarz Pharma
56
神经系统药物开发能力大增
7月24
冰岛Novator(投资公司)
冰岛Actavis(非专利药厂商)
31
Actavis从上市公司转为私营企业
10月1
日本三菱制药
日本田边制药
30
合并后的公司成为日本第六大药商
4月17
英国Shire
美国New River
25
获得重要的新型小儿多动症治疗药物
1月29
美国礼来
ICOS
24
完全控制先前由两家共同开发推广的ED药物希爱力(他达拉非)
2月1
美国Hospira
澳大利亚Mayne
21
在药物注射技术与现有肿瘤产品的全球扩张方面夯实基础

2640 total views, 0 today

Tools


  • No ads viewed yet.